Press Release

Suven Life Sciences will present five scientific posters at a global Alzheimer's conference, detailing updates on its Phase-3 Masupirdine study for Alzheimer's Agitation and Phase-2 Usmarapride program for cognitive disorders, alongside other neuroscience pipeline developments.